MapLight Therapeutics Says IRIS Phase 2 Trial Did Not Meet Its Primary Endpoint; Stock Down 10.5%

MapLight Therapeutics said its IRIS Phase 2 trial failed to meet the primary endpoint in social communication deficits associated with autism spectrum disorder (ASD). The readout is a setback for the company's clinical pipeline and may pressure sentiment around its lead program. Impact is likely company-specific rather than sector-wide.

Analysis

MapLight Therapeutics said its IRIS Phase 2 trial failed to meet the primary endpoint in social communication deficits associated with autism spectrum disorder (ASD). The readout is a setback for the company's clinical pipeline and may pressure sentiment around its lead program. Impact is likely company-specific rather than sector-wide.